Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Complement C5

Complement C5

Brief Information

Name:Complement C5
Target Synonym:C5a,Complement Component 5,ECLZB,Anaphylatoxin C5a Analog,C5a Anaphylatoxin,C5b,C5,Prepro-C5,CPAMD4,Complement C5,C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4,C5D
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:19
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

 Complement C5 ELISA

Immobilized Biotinylated Human Complement C5, His,Avitag (Cat. No. CO5-H82E9) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Monoclonal Anti-Human C5a Human Antibody, Human IgG1 with a linear range of 0.1-3 ng/mL (QC tested).

 Complement C5 ELISA

Immobilized Human Complement C5 Protein, Fc Tag (Cat. No. CO5-H5253) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Human C5a Human Antibody, Human IgG1 with a linear range of 0.5-4 ng/mL (QC tested).

Customer Reviews

Synonym Name

Complement C5,C5,CPAMD4


Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. C5 precursor is first processed by the removal of 4 basic residues, forming two chains, beta and alpha, linked by a disulfide bond. C5 convertase activates C5 by cleaving the alpha chain, releasing C5a anaphylatoxin and generating C5b (beta chain + alpha' chain). Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled. The C5a anaphylatoxin interacts with C5AR1 and tick complement inhibitor. C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Ravulizumab ALXN-1810; ALXN-1210 Approved Alexion Pharmaceuticals Inc, Xencor Inc Ultomiris United States Hemoglobinuria, Paroxysmal Alexion Pharmaceuticals Inc 2018-12-21 Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Dermatomyositis; Glomerulonephritis, IGA; Coronavirus Disease 2019 (COVID-19); Atypical Hemolytic Uremic Syndrome; Respiratory Distress Syndrome, Adult; Lupus Nephritis; Thrombotic Microangiopathies; Acute Kidney Injury; Neuromyelitis Optica; Pneumonia, Viral; Acute Lung Injury; Amyotrophic Lateral Sclerosis Details
Eculizumab LEX-98; h-5G1.1; 5G1-1; HAL-1 Approved Alexion Pharmaceuticals Inc Soliris, 舒立瑞 United States Atypical Hemolytic Uremic Syndrome; Hemoglobinuria, Paroxysmal Alexion Pharmaceuticals Inc 2007-03-16 Neuromyelitis Optica; Macular Degeneration; Diabetes Mellitus; Kidney Failure, Chronic; Thrombocytopenia; Urea Cycle Disorders, Inborn; Guillain-Barre Syndrome; Asthma; Nasopharyngeal Carcinoma; Glomerulonephritis, Membranoproliferative; Pre-Eclampsia; Anemia, Hemolytic, Autoimmune; Myasthenia Gravis; Infant, Newborn, Diseases; Antiphospholipid Syndrome; Delayed Graft Function; Rejection of organ transplantation; Atypical Hemolytic Uremic Syndrome; Vagus Nerve Diseases; Hemoglobinuria, Paroxysmal; Rejection of renal transplantation; HELLP Syndrome; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; End Stage Liver Disease Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
ALXN-5500 ALXN-5500 Phase 1 Clinical Alexion Pharmaceuticals Inc Hemoglobinuria, Paroxysmal Details
Eculizumab biosimilar (CinnaGen) Phase 3 Clinical Cinnagen Hemoglobinuria, Paroxysmal Details
Vilobelimab CaCP-29; IFX-1 Phase 3 Clinical Inflarx Nv Shock, Septic; Granulomatosis with Polyangiitis; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Drug-Related Side Effects and Adverse Reactions; Microscopic Polyangiitis; Pyoderma Gangrenosum; Sepsis; Coronavirus Disease 2019 (COVID-19); Lung Diseases, Interstitial; Hidradenitis Suppurativa; Systemic Inflammatory Response Syndrome Details
Gefurulimab TPP-2511; ALXN-1720; CON-9978 Phase 3 Clinical Alexion Pharmaceuticals Inc Myasthenia Gravis; Proteinuria Details
IM-101 IM-101 Phase 1 Clinical ImmunAbs Inc Autoimmune Diseases Details
Eculizumab biosimilar (IBC GENERIUM) Phase 3 Clinical Ibc Generium Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome Details
Zilucoplan RA-101495-SC; RA-101495 Phase 3 Clinical Ucb Sa, Ra Pharma Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Coronavirus Disease 2019 (COVID-19); Muscular Diseases Details
Eculizumab biosimilar (Amgen) ABP-959 Phase 3 Clinical Amgen Inc Hemoglobinuria, Paroxysmal Details
eculizumab biosimilar(Isu Abxis) ISU-305 Phase 1 Clinical Isu Abxis Co Ltd Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome Details
Pozelimab REGN-3918 Phase 3 Clinical Regeneron Pharmaceuticals Inc Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Protein-Losing Enteropathies Details
Cemdisiran ALN-62643; ALN-CC5; AD-62643 Phase 3 Clinical Alnylam Pharmaceuticals Inc Myasthenia Gravis; Glomerulonephritis, IGA; Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome Details
P-014 P014; KP-104 Phase 2 Clinical Kira Pharmaceuticals LLC Glomerulonephritis, IGA; Hemoglobinuria, Paroxysmal; Kidney Diseases; Lupus Erythematosus, Systemic; Glomerulonephritis Details
STSA-1002 STSA1002; STSA-1002 Phase 1 Clinical Staidson(Beijing) Biopharmaceuticals Co Ltd Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Coronavirus Disease 2019 (COVID-19) Details
Eculizumab biosimilar (Samsung Bioepis) SB-12 Phase 3 Clinical Samsung Bioepis Co Ltd Hemoglobinuria, Paroxysmal Details
CAN-106 CAN-106 Phase 2 Clinical Beihai Kangcheng (Beijing) Pharmaceutical Technology Co Ltd Hemoglobinuria, Paroxysmal; Genetic Diseases, Inborn Details
BDB-001 BDB-001; BDB001; BDB 001; BDB-1 Phase 3 Clinical Staidson(Beijing) Biopharmaceuticals Co Ltd Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Solid tumours; Coronavirus Disease 2019 (COVID-19); Hidradenitis Suppurativa Details
Nomacopan rEV-576; EV-576; rVA576 Phase 3 Clinical Evolutec Hemoglobinuria, Paroxysmal; Thrombotic Microangiopathies; Pemphigoid, Bullous; Keratoconjunctivitis; Macular Degeneration Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message